Biography for Tracy Staton
Tracy Staton, Senior Editor
Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at email@example.com or find her on LinkedIn.
Articles by Tracy Staton
Companies have been studying Stendra for some sort of competitive edge. Now, they may have found one: The FDA backed the ED pill as a fast-acting treatment, taken 15 minutes before sex. Previously, the directions prescribed a 30-minute lead time.
CVS Health has some hard data on Sovaldi's excursion from the Gilead Sciences clinic and into the world. It's not encouraging: More than four times as many real-world patients are dropping off the pricey hepatitis C treatment than in clinical trials.
An FDA advisory panel wants to limit the use of testosterone drugs for safety reasons--and the proposed restrictions would shrink sales significantly. That's not good news for AbbVie, the market leader, and other drugmakers that have been riding a surge of testosterone growth.
When it comes to launching a next-generation drug, first is always best, right? Press releases can call it a "first-in-class" product. Sales and marketing teams can get a leg or two up on any follow-up rivals. What's not to like? McKinsey & Co. wanted to find out.
AstraZeneca's brand-new Movantik has an edge on rivals in the opioid-induced constipation (OIC) market, which is expected to near $2 billion by 2017. It's the first mu-opioid approved for OIC, and the first mu-opioid pill, period.
Plenty of drugmakers are chasing opportunity in diabetes. The fast-growing epidemic means new therapies are sorely needed. But dealing with diabetes directly isn't the only strategy. Regeneron figures it can score by treating some of the disease's long-term complications.
Next month, the FDA's expert advisers will take another look at Pfizer's stop-smoking drug Chantix. The official agenda: Weigh new data on Chantix's links to psychiatric side effects, and consider changing the black-box warning about those risks.
So much for home field advantage. Switzerland plans to put the squeeze on drug prices, despite its corporate citizens Roche and Novartis. And the Basel-based companies are none too happy about the idea.
Pfizer and Ranbaxy Laboratories persuaded a U.S. judge to toss out an antitrust lawsuit accusing them of conspiring to delay generic versions of the cholesterol-fighting blockbuster Lipitor.
Gilead Sciences has cracked the door on its pricing for the hepatitis C combo pill it's hoping to roll out next month. And here's the view: No "significant premium" to the current three-drug cocktail that includes Sovaldi, Gilead's current money-minting treatment.